152 related articles for article (PubMed ID: 34442335)
21. Assessment of MYCN amplification status in Tunisian neuroblastoma: CISH and MLPA combining approach.
H'Mida Ben Brahim D; Trabelsi S; Chabchoub I; Gargouri I; Harrabi I; Moussa A; Chourabi M; Haddaji M; Sassi S; Mougou S; Gribaa M; Ben Ahmed S; Zakhama A; Nouri A; Saad A
Tunis Med; 2015; 93(8-9):527-31. PubMed ID: 26815518
[TBL] [Abstract][Full Text] [Related]
22. Overall genomic pattern is a predictor of outcome in neuroblastoma.
Janoueix-Lerosey I; Schleiermacher G; Michels E; Mosseri V; Ribeiro A; Lequin D; Vermeulen J; Couturier J; Peuchmaur M; Valent A; Plantaz D; Rubie H; Valteau-Couanet D; Thomas C; Combaret V; Rousseau R; Eggert A; Michon J; Speleman F; Delattre O
J Clin Oncol; 2009 Mar; 27(7):1026-33. PubMed ID: 19171713
[TBL] [Abstract][Full Text] [Related]
23. Neuroblastoma epigenetics: from candidate gene approaches to genome-wide screenings.
Decock A; Ongenaert M; Vandesompele J; Speleman F
Epigenetics; 2011 Aug; 6(8):962-70. PubMed ID: 21725203
[TBL] [Abstract][Full Text] [Related]
24. Downregulation of PIF1, a potential new target of MYCN, induces apoptosis and inhibits cell migration in neuroblastoma cells.
Chen B; Hua Z; Gong B; Tan X; Zhang S; Li Q; Chen Y; Zhang J; Li Z
Life Sci; 2020 Sep; 256():117820. PubMed ID: 32512012
[TBL] [Abstract][Full Text] [Related]
25. Shallow Whole Genome Sequencing on Circulating Cell-Free DNA Allows Reliable Noninvasive Copy-Number Profiling in Neuroblastoma Patients.
Van Roy N; Van Der Linden M; Menten B; Dheedene A; Vandeputte C; Van Dorpe J; Laureys G; Renard M; Sante T; Lammens T; De Wilde B; Speleman F; De Preter K
Clin Cancer Res; 2017 Oct; 23(20):6305-6314. PubMed ID: 28710315
[No Abstract] [Full Text] [Related]
26. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
[TBL] [Abstract][Full Text] [Related]
27. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
28. [Abnormality of anaplastic lymphoma kinase gene and its expression in pediatric neuroblastoma].
Chen S; Zhou C; Ma X; Gong L
Zhonghua Bing Li Xue Za Zhi; 2014 Aug; 43(8):541-5. PubMed ID: 25346125
[TBL] [Abstract][Full Text] [Related]
29. Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment.
Lambertz I; Kumps C; Claeys S; Lindner S; Beckers A; Janssens E; Carter DR; Cazes A; Cheung BB; De Mariano M; De Bondt A; De Brouwer S; Delattre O; Gibbons J; Janoueix-Lerosey I; Laureys G; Liang C; Marchall GM; Porcu M; Takita J; Trujillo DC; Van Den Wyngaert I; Van Roy N; Van Goethem A; Van Maerken T; Zabrocki P; Cools J; Schulte JH; Vialard J; Speleman F; De Preter K
Clin Cancer Res; 2015 Jul; 21(14):3327-39. PubMed ID: 25805801
[TBL] [Abstract][Full Text] [Related]
30. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.
Chen QR; Bilke S; Wei JS; Whiteford CC; Cenacchi N; Krasnoselsky AL; Greer BT; Son CG; Westermann F; Berthold F; Schwab M; Catchpoole D; Khan J
BMC Genomics; 2004 Sep; 5():70. PubMed ID: 15380028
[TBL] [Abstract][Full Text] [Related]
31. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
[TBL] [Abstract][Full Text] [Related]
32. Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma.
Ochiai H; Takenobu H; Nakagawa A; Yamaguchi Y; Kimura M; Ohira M; Okimoto Y; Fujimura Y; Koseki H; Kohno Y; Nakagawara A; Kamijo T
Oncogene; 2010 May; 29(18):2681-90. PubMed ID: 20190806
[TBL] [Abstract][Full Text] [Related]
33. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.
Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E
Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175
[TBL] [Abstract][Full Text] [Related]
34. Genetic Alterations Detected by Targeted Next-generation Sequencing and Their Clinical Implications in Neuroblastoma.
Koh KN; Lee JY; Lim J; Shin J; Kang SH; Suh JK; Kim H; Im HJ; Namgoong JM; Kim DY; Jang SJ; Chun SM
Anticancer Res; 2020 Dec; 40(12):7057-7065. PubMed ID: 33288603
[TBL] [Abstract][Full Text] [Related]
35. Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastoma.
Cazes A; Louis-Brennetot C; Mazot P; Dingli F; Lombard B; Boeva V; Daveau R; Cappo J; Combaret V; Schleiermacher G; Jouannet S; Ferrand S; Pierron G; Barillot E; Loew D; Vigny M; Delattre O; Janoueix-Lerosey I
Cancer Res; 2013 Jan; 73(1):195-204. PubMed ID: 23139213
[TBL] [Abstract][Full Text] [Related]
36. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma.
Chava S; Reynolds CP; Pathania AS; Gorantla S; Poluektova LY; Coulter DW; Gupta SC; Pandey MK; Challagundla KB
Mol Oncol; 2020 Jan; 14(1):180-196. PubMed ID: 31637848
[TBL] [Abstract][Full Text] [Related]
37. Identifying a wide range of actionable variants using capture-based ultra-deep targeted sequencing in treatment-naive patients with primary lung adenocarcinoma.
Chen L; Chen M; Lin J; Chen X; Yu X; Chen Z; Jin L
Int J Clin Exp Pathol; 2020; 13(3):525-535. PubMed ID: 32269691
[TBL] [Abstract][Full Text] [Related]
38. Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations.
Bosse KR; Maris JM
Cancer; 2016 Jan; 122(1):20-33. PubMed ID: 26539795
[TBL] [Abstract][Full Text] [Related]
39. Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets.
Sahm F; Schrimpf D; Jones DT; Meyer J; Kratz A; Reuss D; Capper D; Koelsche C; Korshunov A; Wiestler B; Buchhalter I; Milde T; Selt F; Sturm D; Kool M; Hummel M; Bewerunge-Hudler M; Mawrin C; Schüller U; Jungk C; Wick A; Witt O; Platten M; Herold-Mende C; Unterberg A; Pfister SM; Wick W; von Deimling A
Acta Neuropathol; 2016 Jun; 131(6):903-10. PubMed ID: 26671409
[TBL] [Abstract][Full Text] [Related]
40. Combined Replenishment of miR-34a and let-7b by Targeted Nanoparticles Inhibits Tumor Growth in Neuroblastoma Preclinical Models.
Di Paolo D; Pastorino F; Brignole C; Corrias MV; Emionite L; Cilli M; Tamma R; Priddy L; Amaro A; Ferrari D; Marotta R; Ferretti E; Pfeffer U; Ribatti D; Sementa AR; Brown D; Ikegaki N; Shimada H; Ponzoni M; Perri P
Small; 2020 May; 16(20):e1906426. PubMed ID: 32323486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]